Wall Street analysts expect Orthofix Medical Inc (NASDAQ:OFIX) to announce $122.45 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Orthofix Medical’s earnings, with estimates ranging from $121.90 million to $123.00 million. Orthofix Medical reported sales of $116.90 million during the same quarter last year, which would suggest a positive year over year growth rate of 4.7%. The firm is expected to report its next quarterly earnings report on Monday, February 25th.

According to Zacks, analysts expect that Orthofix Medical will report full year sales of $453.70 million for the current financial year, with estimates ranging from $453.50 million to $453.90 million. For the next financial year, analysts anticipate that the firm will post sales of $479.85 million, with estimates ranging from $478.90 million to $480.80 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Orthofix Medical.

Orthofix Medical (NASDAQ:OFIX) last issued its earnings results on Monday, October 29th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Orthofix Medical had a return on equity of 10.97% and a net margin of 1.45%. The firm had revenue of $111.70 million for the quarter, compared to the consensus estimate of $110.65 million. During the same quarter in the prior year, the business earned $0.42 earnings per share. The company’s revenue was up 6.2% compared to the same quarter last year.

A number of analysts have recently commented on OFIX shares. BidaskClub downgraded Orthofix Medical from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 17th. TheStreet downgraded Orthofix Medical from a “b” rating to a “c+” rating in a research report on Wednesday, August 1st. Cantor Fitzgerald increased their price target on Orthofix Medical to $66.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 7th. Finally, Zacks Investment Research downgraded Orthofix Medical from a “hold” rating to a “sell” rating in a research report on Thursday, August 9th. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $67.67.

In other Orthofix Medical news, CEO Brad Mason sold 2,500 shares of the stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $53.02, for a total transaction of $132,550.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Rice Doug sold 6,057 shares of the stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $61.25, for a total value of $370,991.25. Following the transaction, the chief financial officer now owns 26,511 shares in the company, valued at approximately $1,623,798.75. The disclosure for this sale can be found here. Insiders have sold 28,343 shares of company stock worth $1,690,376 in the last quarter. 5.60% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of OFIX. First Quadrant L P CA acquired a new position in shares of Orthofix Medical during the third quarter valued at approximately $122,000. Itau Unibanco Holding S.A. acquired a new position in shares of Orthofix Medical during the second quarter valued at approximately $224,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Orthofix Medical during the second quarter valued at approximately $227,000. Suntrust Banks Inc. acquired a new position in shares of Orthofix Medical during the first quarter valued at approximately $256,000. Finally, Hartford Investment Management Co. acquired a new position in shares of Orthofix Medical during the second quarter valued at approximately $269,000. Institutional investors own 92.64% of the company’s stock.

Shares of OFIX traded down $0.69 during mid-day trading on Friday, reaching $61.68. The company had a trading volume of 120,177 shares, compared to its average volume of 190,507. Orthofix Medical has a 52-week low of $50.41 and a 52-week high of $63.57. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 38.07, a PEG ratio of 3.62 and a beta of 0.30.

Orthofix Medical Company Profile

Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.

Featured Article: What does cost of debt say about a company’s financial health?

Get a free copy of the Zacks research report on Orthofix Medical (OFIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthofix Medical (NASDAQ:OFIX)

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.